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The effect of interleukin 1 (IL-l) on gh~cose transport activity in isolated rat adipose cells was examined. IL-IS stimulated 3-O-methylglucose 
(30MG) transport in a time and dose dependent manner. This effect appears to be due to increased maximal transport velocity (Vmu) of the carrier. 
Addition of insulin and IL-l/J resulted in an additive stimulation of transport, suggesting different mechanisms. IL-la had no effect on glucose 
transport. Glu-4, a relatively inactive IL-l/J analogue in most cells, stimulated glucose uptake in a time and dose dependent manner with kinetics 
indistinguishable from those of IL-l/I. - 
lnterleukin 1-p; lnterleukin 1-b receptor; Glucose transport; Cytokine; Cachexia 
1. INTRODUCTION 
Cytokines play a central role in the host’s response to 
infection. In addition to direct effects on cells of the im- 
mune system, they induce a variety of metabolic 
changes, including anorexia, loss of body protein and 
fat, changes in blood leukocyte patterns and hepatic 
secretory protein synthesis, trace mineral redistribution 
and other variations in carbohydrate and fat utilization 
[l]. While generally recognized as promoting host 
recovery, if prolonged, these host alterations may lead 
to severe tissue wasting and organ failure. A better 
understanding of the cellular effects of cytokines will 
provide insight into the sequence of cytokine actions 
that occur during the host response to infection. 
Interleukin 1 (IL-l), one of several monocyte derived 
polypeptide hormones, is a primary mediator of the 
host’s response to infection [2]. IL-l induces fever, slow 
wave sleep, the synthesis of hepatic acute phase pro- 
teins, and the release of neutrophils, ACTH, cortisol, 
and insulin [ 1,3-61. Cachexia, characterized by tissue 
wasting and negative nitrogen balance, often accom- 
panies chronic infections including sepsis and inflam- 
matory disease [7]. IL-l contributes to this process at 
several levels, including the inhibition of lipoprotein 
lipase activity and synthesis [g], decreasing utilization 
of fat for energy. Cachexia also results in alterations in 
glucose homeostasis, manifested by a severe hypo- 
glycemia [9]. Studies examining IL-l’s effects on 
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glucose metabolism are difficult to evaluate as they are 
either done in vivo [lO-121, where the influence of other 
cytokines may affect the response, or use crude 
monokine preparations, where the contribution of IL-l 
to the response may be modified [ 13- 151. 
The studies described in this communication were 
designed to determine the effects of IL-l on glucose 
transport in isolated rat adipose cells. We present 
evidence that IL-10 stimulates glucose transport in in- 
tact adipose cells in a time and dose dependent manner, 
and demonstrate differential effects of IL-16 and IL-la 
as well as Glu-4, and IL-l analogue. Elucidation of the 
mechanism of action of IL-l on glucose transport 
should provide further insight into the regulation of the 
glucose carrier. 
2. EXPERIMENTAL 
2.1. Materials 
IL-la and 8, as well as the IL-1 analogue, Glu-4, were gifts from 
Dr. R.C. Newton from Du Pont De Nemours & Co. Crude col- 
lagenase (Type I) was purchased from Worthington (Freehold, NJ), 
and bovine serine albumin, fraction V, was purchased from Armour 
Pharmaceutical Co (Kankakee, IL). All other reagent grade 
biochemicals were from Sigma (St Louis, MO). 
2.2. Animals and cell preparation 
Male Sprague-Dawley rats (160-180 g) were obtained from Taconic 
Farms (Germantown, NY). Animals were fed laboratory chow 
(Ralston Purina, St. Louis, MO) ad libitum and were killed by CO2 
asphyxiation. Isolated adipocpes were obtained by collagenase diges- 
tion of the epididymal fat pad as described by Rodbell [16] and 
modified by Cushman and Wardzala [17]. All incubations were car- 
ried out at 37’C in a KRBH buffer, pH 7.4, containing 10 mM sodium 
bicarbonate, 30 mM Hepes, 5% bovine serum albumin. The exact ex- 
perimental conditions are described in the figure legends. Briefly, 
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adipose cells were incubated for various lengths of time under basal 
conditions (no hormone added) or in the presence of either 7 nM in- 
sulin or various concentrations of IL-Ifi, IL-la, or Glu-4 and 3-O 
methylglucose uptake measured. In the studies using cycloheximide, 
isolated adipose cells were incubated with or without cycloheximide 
(10 pg/ml) for 30 min followed by an additional 2 l/2 h in the 
presence of 7 nM IL-l. A concentration of 10 pg/ml was chosen as 
this concentration was found to inhibit [3H]leucine incorporation into 
protein 90% [l&J]. 
2.3. Measurement of glucose transport activity 
In all experiments, glucose transport was determined by measuring 
the rapid uptake of “C-3-O-(methyl)D-glucose as described by 
Gliemann and Whitesell [19] and modified by Foley et al. [20]. 
Transport under basal and maximally stimulating insulin concentra- 
tions (7 nM) was measured routinely following a 30 min incubation 
period, and at the end of longer incubation times, to demonstrate nor- 
mal insulin sensitivity. 
3. RESULTS AND DISCUSSION 
Fig. 1A shows the time course of IL-10 stimulation of 
30MG uptake in isolated rat adipose cells. The max- 
imum response, a 4-fold increase above the rate of basal 
transport, is achieved after 180 min, after a half time of 
75 min. This slow time course of glucose transport ac- 
tivation contrasts strongly with the rapid activation of 
transport observed with insulin (half time of 2.5 min) 
[21]. Interestingly, the ability of IL-l@ to stimulate 
30MG uptake in adipose cells is more rapid than that 
previously reported in L-6 muscle cells [14]. However, 
this probably reflects the fact that the L-6 cells were 
treated with a crude monokine preparation which con- 
tained an unknown quantity of factors. Fig. 1B shows 
that IL-l/3 stimulates glucose transport in intact adipose 
cells in a dose dependent manner. The maximum 
response, a 4-fold increase above the basal rate of 
transport, required an IL-l/3 concentration of 7 nM. 
Half maximal stimulation of transport by IL-l@ occur- 
red at 0.2 nM which is a physiologically relevant 
WI. 
The mechanism of action on IL-1B on glucose 
transport could be due to either an increase in the max- 
imal transport velocity (I’,,,,) or an increase in the af- 
finity (Km) of the glucose transporter by the cytokine. 
In order to distinguish between these two possibilities 
glucose uptake was measured at varying substrate con- 
centrations. The kinetic data from these experiments, 
summarized in Table I, demonstrate that the effects of 
IL-la on glucose transport are due to an increase in the 
maximal transport velocity. Interleukin 1 had no effect 
on the K,,, for glucose uptake, suggesting a mechanism 
of action distinct from that of insulin which showed 
changes in both the K,,, and I&.. 
The increased V,, in IL-l treated cells can be ac- 
counted for by either (i) recruitment of carriers from an 
intracellular pool to the plasma membrane, (ii) an ab- 
solute increase in the number of glucose carriers via an 
increase in de novo protein synthesis, or (iii) changes in 
the intrinsic activity of the carrier [18]. Given the 
relatively slow time course of IL-l action on glucose 
transport, the involvement of de novo synthesis eems 
likely and we tested this by incubating adipose cells in 
the presence of saturating concentrations of IL-10 (7 
nM) with or without cycloheximide (10 pg/ml). 
Cycloheximide treatment blocked the ability of IL-l/3 to 
stimulate glucose transport by 40%. 3-O-methylglucose 
uptake in cycloheximide-treated cells averaged 0.1% f 
0.026 fmol/cell/min compared to 0.3 13 f 0.05 1 fmol/ 
cell/min in cells incubated in the absence of cyclohex- 
imide. 
The partial inhibition of IL-la stimulation of glucose 
transport by cycloheximide suggests that the cytokine 
stimulates glucose transport activity via an increase in 
de novo protein synthesis. Further evidence in favor of 
this notion comes from experiments in which insulin 
and IL-l were used to stimulate transport activity either 
alone or together. As can be seen in Table II, insulin in- 
creased glucose transport activity 34-fold above basal 
1 10 
IL-1 Concentration (nM) 
Fig. 1. Time course and concentration dependency of IL-l@ and Glu-4 to stimulate Glucose Transport. (A) Isolated adipose cells were incubated 
in the presence of either 7 nM IL-10 [=I or Glu-4 [Cl] for the times indicated. (B) Isolated adipose cells were incubated for 3 h in the presence 
of varying concentrations (O-SO nM) of either IL-16 [m]or Glu-4 (0). 3-O-Methyl glucose uptake was measured as described in section 2. The values 
represent the fold stimulation of glucose uptake over basal levels by both IL-1j.I and Glu-4 from four separate xperiments. Zero on the y-axis 
represents uptake under basal conditions (i.e. no stimulation). In these experiments basal and insulin stimulated 3-O-methyl glucose uptake was 
0.100 f 0.005 and 2.99 it 0.310 respectively, after 30 min and 0.105 f 0.005 and 3.86 f 0.710 after 3 h. 
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Table I 
Kinetic analysis of IL-1 stimulated glucose transport 
V mu Km 
(fmol 
glucose/cell/min) (mM) 
Basal 7.1 f 1.2. 8.8 f 0.6” 
IL-l 33.0 f 11.0s 12.2 f 2.6* 
Insulin 206.0 f 17.oE 3.4 f 0.P 
Values represent mean f SE from 5 separate xperiments. Within a 
column, values with different superscripts are significantly different 
at the P < 0.05 level. Isolated adipose cells were incubated with 
varying concentrations of glucose (O-46 mM) under basal conditions 
(no additions) or in the presence of either 7 nM IL-16 or insulin. The 
uptake of 3-O-methyl glucose was determined as described in section 
2. The uptake data from these experiments was analyzed by a Woolfe- 
Augustinsson plot (V vs V/S’) [35]. 
Table 11 
Effects of insulin and IL-16 on glucose transport activity in isolated 
rat adiwse cells 
Conditions 
3-O-Methyl glucose 
uptake 
(fmol/cell/min) (fold stimulation) 
BasaI 0.10 f 0.02 
Insulin 3.20 f 0.50 34.0 f 4.0 
IL-10 0.38 f 0.10 3.9 f 0.2 
Insulin + IL-10 3.98 f 0.40 40.0 f 4.0 
Values represent mean f SE from 4 separate experiments. Fold 
stimulation represents the rate of glucose uptake in the presence of 
hormone divided by the rate of glucose uptake in the absence of 
hormone (basal). Isolated adipose cells were incubated under basal 
conditions (no treatment), and in the presence of 7 nM insulin and 7 
nM IL-I& either separately or in combination, for 3 h. 3-O-Methyl 
glucose uptake was measured at the end of the incubation period as 
described in section 2. 
levels, IL-16 increased transport by 4-fold, and the two 
hormones acting together increased glucose transport 
activity 40-fold above basal levels. Our interpretation 
of these findings is that IL-1 is stimulating transport ac- 
tivity by increasing de novo protein synthesis while in- 
sulin, which does not affect transporter synthesis, in- 
creases transporter activity by translocating carriers 
from an intracellular location to the plasma membrane 
[17]. Thus, the effects of the two hormones, which 
stimulate glucose transport activity by different 
mechanisms, are additive. 
Interestingly, when adipose cells, incubated in the 
presence and absence of 7 nM IL-l& were assayed for 
transporter numbers by the D-glucose inhibitable 
cytochalasin B binding assay [17], we did not see any 
difference in carrier numbers between untreated and 
treated cells, 7 f 2 compared to 8 it 2 pmol/mg pro- 
tein, respectively. In the same experiments, plasma 
membranes from insulin-treated cells had an increased 
number of glucose carriers, averaging 25 f 5 pmol/mg 
of protein. These data suggest hat the mechanism of 
IL-l/3 action on glucose transport does not involve the 
translocation of glucose carriers as has been shown for 
insulin. However, since IL-l/3 stimulates glucose uptake 
only 4-fold above basal levels, we anticipate this would 
result in only small changes in the distribution of 
glucose transporters which may not be detected given 
the insensitivity of the cytochalasin B binding assay. 
Given the finding that IL-16 stimulates glucose up- 
take in adipose cells, we wondered whether Il-lo would 
have a similar effect. In most cells and tissues, IL-lo 
and IL-l/3 share similar biological properties despite 
having only a 25% sequence homology [2,3]. In con- 
trast to the effects of IL-l/3 on glucose transport activi- 
ty, IL-lo had no effect, even at a concentration (70 nM) 
ten times greater than that of IL-10 (Table III). It is 
unlikely that these data can be explained on the basis of 
variation in the quality of the cytokine preparations 
since both IL-lo and IL-l@ were equipotent in their 
ability to stimulate thymocyte proliferation in the com- 
itogenic assay for IL-l bioactivity (data not shown) 
[22]. In line with our findings, several recent reports 
have suggested that IL-lo and IL-10 do not always 
share the same profile of biological activities [23-251. 
Furthermore, it is now well recognized that there are at 
least two classes of IL-1 receptor; ~80, an 80 kDa single 
chain protein found in T-cells, fibroblasts and many 
other cell types, and ~68, a 68 kDa protein expressed in 
B-cells and macrophages [26-281. The two classes of 
IL-l receptor show distinct differences in their substrate 
binding site and molecular properties. Although we 
have not formally provided evidence of IL-l receptors 
on adipose cells, the time and dose dependent nature of 
IL-l’s ability to stimulate glucose transport suggests 
that the effect is most likely mediated via binding to a 
cell surface IL-1 receptor. Consistent with this idea, 
Katsuura et al. [29] have demonstrated that purified 
IL-lj3 receptor from rat brain does not recognize IL-la. 
Further evidence in support of the idea that the 
disparate effects of II-la and IL-10 on glucose 
transport are IL-1 receptor mediated comes from ex- 
periments with an IL-10 analog, Glu-4. This analog of 
Table III 
Effect of IL-la on glucose transport activity in isolated rat adipose 
cells 
3-O-Methyl glucose 
uptake 
Conditions Concentration (fmol/cell/min) 
(nM) 
Basal 0.106 f 0.010 
IL-16 7 0.337 f 0.071 
IL-la 7 0.131 f 0.030 
IL-la 70 0.112 f 0.0651 
IL-la 110 0.254 f 0.029 
Values represent mean f SE from 4 separate xperiments. Isolated 
adipose cells were incubated under basal conditions (no treatment), in 
the presence of 7 nM IL-16 or various concentrations of IL-la for 3 
h. 3-O-Methyl glucose uptake was measured at the end of the 
incubation period. Insulin stimulated uptake at the end of the 
incubation was 3.39 f 0.620 fmol/cell/min. 
423 
Volume 269, number 2 FEBS LETTERS September 1990 
IL-ID has a substitution at residue four at the N- 
terminal end from Arg to Glu [30]. Glu-4 has been 
shown to have only 0.2% of the biological activity of 
IL-l@ in EL-4 cells (p80 receptor) but 30% binding to 
Raji cells (p68 receptor) [26,30]. As can be seen in Fig. 
1, Glu-4 stimulates glucose transport in a time and dose 
dependent manner. Indeed, the time course of glucose 
transport stimulation by 7 nM Glu-4 is identical to that 
of IL-l& The data suggest hat Glu-4 is equipotent with 
IL-10 and is a full agonist. 
In conclusion, our studies demonstrate that IL-10 but 
not IL- 1 OL can stimulate glucose transport in rat adipose 
cells. An II-l/3 analogue, Glu-4, inactive in most cells, 
was able to fully stimulate glucose transport. Our inter- 
pretation of these data are that the differences in the 
ability of II-la! and II-l/3 to stimulate glucose transport 
are probably due to differences in their ability to bind 
to the adipose cell IL-l receptor. Furthermore based on 
the substrate profile of the adipose cell IL-l receptor, 
we speculate that it is most likely the p68 type, since this 
receptor discriminates between IL-la and IL-10 and 
shows reasonable binding kinetics for Glu-4 which is in- 
active on p80 receptors [26,30]. The ability of IL-16 to 
stimulate glucose transport together with its ability to 
suppress lipoprotein lipase activity [8] suggest hat this 
cytokine may play a critical role in regulating fuel 
homeostasis during chronic disease. 
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